medigraphic.com
ISSN 1561-2988 (Print)

2011, Number 3

<< Back Next >>

Rev Cubana Farm 2011; 45 (3)

Cannabinoids and their possible use in the treatment of glaucoma

Zozaya AB, Medina RI, Tamayo PN

Language: Spanish
References: 34
Page: 439-448
PDF size: 165.35 Kb.


ABSTRACT

Although the Cannabis Sativa plant has been used since the most remote ancient times for medicinal purposes, one of its derivatives, marijuana, has become the most commonly used illegal drug in the world. Similarly, both Cannabis and the cannabinoids are used therapeutically in a small number of general neurological pathologies. Literature review was made to set forth the possible use of cannabinoids in the treatment of Glaucoma. To this end, t the available literature on the subject from January to September 2010 was taken into account. The cannabinoid´s antihypertensive occular effect has been found to decrease aqueous humor production, and to increase the excretion of aqueous humor through the trabeculary mesh and the route uveoscleral pathway. This effect is compatible with the high concentrations of rCB1 and rCB2 cannabinoid receptors found. Besides, tetrahydrocannabinol has proved to reduce the neurodegenerative effect in models of cerebral ischemia in rats and the beneficial effect of cannabinoids to reduce gluthamate excitotoxicity-mediated secondary degeneration associated with glaucoma. These findings about the beneficial effect of cannabinoids as ocular antihypertensives and its neuroprotective effect convey a hopeful message about the role they could play in the treatment of glaucoma; however, it would be necessary to perform further clinical trials to assess their applicability in our daily clinical practice for greater safety and efficiency.


REFERENCES

  1. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction [Internet] 1996 [cited 2010 Feb15]; 91:1585-1614. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/8972919

  2. Aguar O. Drogas y fármacos de abuso. Madrid: Consejo General de COF; 1981.

  3. Duran M, Laporte JR, Capellà D. Novedades sobre las potencialidades terapéuticas del Cannabis y el sistema cannabinoide. Med Clin (Barc). [Internet] 2004 [citado 10 Sept 2010]; 122(10):390-8. Disponible en: http://preview.ncbi.nlm.nih.gov/pubmed/15033046

  4. Breivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry [Internet] 2009 [cited 2010 Sept 15]; 21(2):113-21. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19367505

  5. Karanian DA, Bahr BA. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr Mol Med [Internet] 2006 [cited 2010 Sept 11]; 6(6):677-84. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/17022737

  6. Fisar Z. Phytocannabinoids and endocannabinoids. Curr Drug Abuse Rev [Internet] 2009 [cited 2010 Sept 10]; 2(1):51-75. Available from: http://preview.ncbi.nlm.nih.gov/pubmed /19630737

  7. Snider NT, Walker VJ, Hollenberg PF. Oxidation of endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxigenases: physiological and pharmacological implications. Pharmacol Rev [Internet] 2010 [cited 2010 Ago 9]; 62(1):135-54. Available from: http://preview.ncbi.nlm.nih.gov/pubmed?term=Oxidation%20of%20endogenous%20cannabinoid%20arachidonoyl%20ethanolamide%20by%20the%20cytochrome%20P450%20monooxigenases%3A%20physiological%20and%20pharmacological%20implications

  8. Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev [Internet] 2009 [cited 2010 Ago 10]; 60(1):255-66. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19150370

  9. Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry [Internet] 2009 [cited 2010 Ago 10]; 21(2):143-51. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19367508

  10. Ralevic V, Kendall DA. Cannabinoid modulation of perivascular sympathetic and sensory neurotransmission. Curr Vasc Pharmacol. [Internet] 2009 [cited 2010 Ago 15]; 7(1):15-25. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19149636

  11. Galal AM, Slade D, Gul W, El-Alfy AT, Ferreira D, Elsohly MA. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Pat CNS Drug Discov [Internet] 2009 [cited 2010 Sept 1]; 4(2):112-36. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19519560

  12. Kreitzer FR, Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther [Internet] 2009 [cited 2010 Sept 12]; 122(2):83-96. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19248809

  13. Panagis G, Vlachou S, Nomikos GG. Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Curr Drug Abuse Rev [Internet] 2008 [cited 2010 Ago 23]; 1(3):350-74. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19630731

  14. Fisar Z. Cannabinoids and atherosclerosis. Prague Med Rep [Internet] 2009 [cited 2010 Sept 2]; 110(1):5-12. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19591373

  15. Karst M, Wippermann S. Cannabinoids against pain. Efficacy and strategies to reduce psichoactivity. A clinical perspective. Expert Opin Investig Drugs [Internet] 2009 [cited 2010 Ago 12]; 18(2):125-33. Available from: http://preview.ncbi.nlm.nih.gov/pubmed?term=%20Cannabinoids%20against%20pain.%20Efficacy%20and%20strategies%20to%20reduce%20psichoactivity

  16. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining Tetrahydrocannabinol and cannabidiol. Med Hypotheses [Internet] 2006 [cited 2010 Sept 10]; 66(6):234-46. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/16209908

  17. Lange JM, Kruse C. Medicinal Chemical Strategies to CB1 cannabinoid receptor antagonists. DDT 2005; 10(10):693-702.

  18. Zajicek J, UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomiced placebo-controlled trial. Lancet [Internet] 2003 [cited 2010 Sept 18] [citado 18 Sept 2010]; 362(9385), 517-1526. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/14615106

  19. Pi-Sunyer X. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients RIO-North America: A Randomized Controlled Trial JAMA [Internet] 2006 [cited 2010 Sept 18]; 295:761-775. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/16478899

  20. Després JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med [Internet] 2005 [cited 2010 Ago 24]; 353: 2121-2134. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/16291982

  21. Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am [Internet] 2005 [cited 2010 Sept 18]; 18:597-609. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/16314222

  22. Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord [Internet] 2005 [cited 2010 Sept 16]; 4(6):677-84. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/16375685

  23. Ruiz-Moreno JM, Montero JA, Bayon A, Rueda J, Vidal M. Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit. Exp Eye Res [Internet] 2007 [cited 2010 Mar 12]; 84: 342-348. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/1714176

  24. Pinar-Sueiro S, Rodríguez-Puertas R, Manuel I, Rivas A, Vecino, E. Localización de receptores para cannabinoides en el sistema visual como diana terapéutica para la neuropatía óptica glaucomatosa. Soc Esp Neurociencia 2009; 2:144.

  25. Martínez García L, Tacoronte Morales JE, NuñeFigueredo Y, Montalbán M, Cabrera Suárez HR. Potencial terapéutico de los canabinoides como neuroprotectores. Rev Cubana Farm [Internet]. 2007 [citado 2010 Sept 7]; 41(3): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152007000300012&lng=es

  26. Ward MS, Khoobehi A, Lavik EB, Langer R, Young MJ. Neuroprotection of retinal ganglion cells in DBA/2J mice whit GDNF loaded biodegradable microspheres. J Pharm Sci [Internet] 2006 [cited 2010 Sept 15]; 96:558-568. Available from: http://preview.ncbi.nlm.nih.gov/pubmed?term=Neuroprotection%20of%20retinal%20ganglion%20cells%20in%20DBA%2F2J%20mice%20whit%20GDNF%20loaded%20biodegradable%20microspheres

  27. Nucci C, Bari M, Spano A, Corasaniti M, Bagetta G, Maccarrone M, Morrone LA. Potential roles of (endo) cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res [Internet] 2008 [cited 2010 Sept 12]; 173:451-64. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/18929127

  28. Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci [Internet] 2008 [cited 2010 Sept 12]; 85(6):406-16. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/18521010

  29. Levin LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care [Internet] 2008 [cited 2010 Sept 19]; 14(1 Suppl): S11-4. Available from: http://preview.ncbi.nlm.nih.gov/pubmed?term=Levin%20LA%2C%20Peeples%20P.%20History%20of%20neuroprotection%20and%20rationale%20as%20a%20therapy%20for%20glaucoma

  30. Nadolska K, Gooe R. The role of endocannabinoid system in physiological and pathological processes in the eye. Klin Oczna [Internet] 2008 [cited 2010 May 10]; 110(10-12):392-6. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19195174

  31. Nadolska K, Gooe R. Possibilities of applying cannabinoids' in the treatment of glaucoma. Klin Oczna [Internet] 2008 [cited 2010 May 10]; 110(7-9):314-7. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19112869

  32. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol [Internet] 2007 [cited 2010 Apr 1]; 18(2):134-9. Available from: http://preview.ncbi.nlm.nih.gov/pubmed?term=Yee%20RW.%20The%20effect%20of%20drop%20vehicle%20on%20the%20efficacy%20and%20side%20effects%20of%20topical%20glaucoma%20therapy

  33. Määttä M, Puska P. Drug therapy for Glaucoma. Duodecim [Internet] 2009 [cited 2010 May 15]; 125(15):1657-63. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/19769182

  34. Porcella A, Maxia C, Gessa GL, Pani L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur J Neurosci [Internet] 2001 [cited 2010 Mar 15]; 13:409-412. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/11168547




2020     |     www.medigraphic.com